Alterity Therapeutics Ltd: Form 20-F for the period ended Jun 30, 2024
Filed with the SEC on Sep 26, 2024 and accepted by EDGAR at Sep 26, 2024, 16:40 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Income tax | 12 months2023-07-01 to 2024-06-30 | AUD 46.1k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2023-07-01 to 2024-06-30 | −AUD 19.1m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2023-07-01 to 2024-06-30 | −AUD 0.52 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2023-07-01 to 2024-06-30 | −AUD 0.52 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2023-07-01 to 2024-06-30 | −AUD 12.6m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2023-07-01 to 2024-06-30 | AUD 5.7k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2024-06-30 | AUD 12.6m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-06-30 | AUD 19.0m | ifrs-full:CurrentAssets |
| Total assets | At period end2024-06-30 | AUD 19.2m | ifrs-full:Assets |
| Current liabilities | At period end2024-06-30 | AUD 5.4m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2024-06-30 | AUD 5.4m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2024-06-30 | −AUD 214.2m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2024-06-30 | 5,245,115,318 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-24-082281. Last ingested by Listed: Oct 30, 2026, 06:15 ET. Listed shows no prices and gives no investment advice.